tirzepatide pregnancy data Potential risks exist to the fetus if ingested during pregnancy - Tizarotirzepatide Use of this drug is not recommended during pregnancy Tirzepatide and Pregnancy: Navigating the Limited Data Landscape

Mounjaro andpregnancysuccess stories The emergence of tirzepatide, known commercially as Mounjaro and Zepbound, has offered significant advancements in managing type 2 diabetes and chronic weight management.2025年1月29日—Novo Nordisk and Eli Lilly are developing comprehensivepregnancyregistries to track the safety of semaglutide (Ozempic/Wegovy) andtirzepatide... However, a crucial area of concern for many patients and healthcare providers revolves around tirzepatide pregnancy data. Currently, the available information regarding the safety of tirzepatide use during pregnancy is notably limited, leading to cautious recommendations from regulatory bodies and medical expertsGlucagon‐like peptide 1 (GLP‐1) receptor agonists' use ....

Understanding the Current Guidance and Data Limitations

A consensus among various authorities and clinical findings strongly advises against the use of tirzepatide during pregnancy2025年12月23日—Tirzepatide is not allowed during pregnancy. Doctors advise caution due to limited pregnancy data in humans. GLP-1 drugs influence key .... This recommendation is rooted in the fundamental lack of comprehensive human data. Regulatory bodies like the FDA classify semaglutide and tirzepatide as pregnancy category C, a designation indicating that the risks to a fetus cannot be ruled out. The prescribing information for both tirzepatide (Eli Lilly) and semaglutide (Novo Nordisk) explicitly advises against their use in pregnancy due to potential risks and the absence of robust safety data.作者：K Farzam·2024·被引用次数：30—Potential risks exist to the fetus if ingested during pregnancy. Hence, tirzepatide should only be prescribed to pregnant patients of childbearing age when the ...

Furthermore, the prescribing information for Mounjaro and Zepbound reiterates that available data with Mounjaro use in pregnant women are insufficient to evaluate for a drug-related risk of major birth defects, miscarriage, or other adverse outcomes作者：CH Parker·2025·被引用次数：12—There were 22 pregnancies reported;six received tirzepatide, one received semaglutide and 15 where maternal exposure status is unknown. There .... This paucity of information extends to breastfeeding individuals as well, with current guidance suggesting avoidance of tirzepatide during this period. For individuals planning conception, the recommendation is to discontinue tirzepatide at least two months prior to attempting to conceive.Can Mounjaro® (tirzepatide) be used in pregnancy? This precautionary measure is partly due to the drug's half-life, which is approximately 5 days, allowing for a gradual clearance from the system.

Insights from Animal Studies and Early Pregnancy Data

While human data remains scarce, animal studies have provided some insights, though direct extrapolation to human pregnancy outcomes requires careful consideration. Some animal studies have reported a decrease in the weight of offspring after exposure to tirzepatide in pregnancy. The precise implications of these findings for human fetal development are still being investigated.Tirzepatide (Mounjaro®, Zepbound®) - MotherToBaby - NCBI

Preliminary reporting from observed pregnancies suggests a complex picture. In research analyzing GLP-1 receptor agonist (GLP-1 RA) use in early pregnancy, one study noted a total of 22 pregnancies. Of these, six involved women who received tirzepatide, one received semaglutide, and in 15 cases, the maternal exposure status was unknown. While this provides a glimpse into real-world exposures, it highlights the need for larger, more controlled studies. Another area of concern stems from the observation that GLP-1 RA use in early pregnancy is associated with an increased risk of miscarriage, infant malformation, intrauterine death/stillbirth, and low birth weight. Additionally, babies born to mothers prescribed a GLP-1 medication in the 90 days prior to pregnancy were found to be more likely to require a NICU stay compared to babies born to mothers not on such medications.

Fertility Considerations and Unintended Pregnancies

Interestingly, some pharmacologic data suggests that weight-loss drugs like tirzepatide, also known as Mounjaro or Zepbound, may decrease the peak levels of contraceptive medications, potentially affecting their efficacy.Tirzepatide and Pregnancy This has led to warnings and recommendations for women using these weight-loss drugs to utilize effective contraceptionThe FDA notes that in the absence of definitive data, it is best to avoid tirzepatide and GLP-1 RA medications at least two months before pregnancy.. There have been anecdotal reports of women becoming pregnant while taking tirzepatide, underscoring the importance of this contraceptive advisory.Tirzepatide (Mounjaro®, Zepbound®) - MotherToBaby - NCBI Some research even explores the potential for incretin receptor agonism, the mechanism of tirzepatide, to possibly improve fertility in cases of metabolic-related infertility, though this remains an area requiring substantial further investigation.

Ongoing Research and Future Directions

The scientific community is actively working to gather more definitive data on tirzepatide pregnancy outcomes.2025年6月5日—Women using weight-loss drugs have been urged to use effective contraception after dozens have reported becoming pregnant while taking the medication. Pharmaceutical companies, such as Eli Lilly and Novo Nordisk, are developing comprehensive pregnancy registries designed to track the safety of semaglutide (Ozempic/Wegovy) and tirzepatide in pregnant individuals.2025年9月10日—A new Australian study highlights a possible link between GLP-1 use and unintended pregnancies. Researchers have warned that many women ... These registries are critical for building a more robust understanding of potential risks and informing future clinical guidance.

In summary, the current landscape surrounding tirzepatide pregnancy data is characterized by a significant lack of conclusive evidence. While tirzepatide offers therapeutic benefits for specific conditions, its use during pregnancy is generally not recommended due to potential risks and insufficient safety information. Healthcare providers are urged to engage in open discussions with patients regarding family planning and to advise discontinuing tirzepatide prior to conception. Continued research and the establishment of comprehensive pregnancy registries are essential steps toward clarifying the safety profile of tirzepatide in pregnant individuals and their offspring.Tirzepatideis a gastric inhibitory polypeptide (GIP) analog and a GLP-1 receptor agonist. It is used as an antidiabetic medication to treat type 2 diabetes ... The interplay between tirzepatide, Mounjaro, Zepbound, semaglutide, and pregnancy outcomes remains a critical area of ongoing medical inquiry, with a growing emphasis on collecting more data to ensure patient safety.作者：RF Drummond·2025—26 However, similar to metformin, there areinsufficient data regarding short- and long-term effects on offspring. The safety box warning on the manufacturer of ...